Nymox reports new positive results from benign prostatic hyperplasia study

A total of 67 patients and controls in this multi-center US study consisting of 92% of eligible patients were followed for an average of 59 weeks after a single administration of NX-1207. Of the patients given full dose NX-1207, 76.7% required no further treatment compared to 37.5% for controls (statistically significant, p=.012).

According to the company, the subjects who received NX-1207 and received no further treatment maintained a mean improvement of 8.9 points in their benign prostatic hyperplasia (BPH) symptom scores which corresponds to a 38% reduction in symptoms from baseline, compared to 2.8 points or a 15% reduction in symptoms for controls. This improvement in symptom score after a single administration of NX-1207 was statistically significant (p=.038).

NX-1207 is a novel drug developed by Nymox which is in Phase III development for the treatment of BPH. The drug has successfully completed a series of blinded controlled multi-center US clinical trials where it has been found to produce improvements that are about double that reported for currently approved BPH drugs.

Paul Averback, CEO of Nymox, said: “We are extremely pleased with these new results, which are remarkably similar to the findings of a completely separate but comparable study reported in 2007. The consistent therapeutic response in a totally different trial in different subjects is very sound.”